Skip to Main Content
Don't have an account? Create Account
Don't have an account? Create Account

DEA Eliminates X-Waiver for Buprenorphine Treatment

Pursuant to the Consolidated Appropriations Act, 2023, the Drug Enforcement Administration (DEA) announced the elimination of the DATA-Waiver Program in a Jan. 12 letter to registered prescribers.

Also known as the X-Waiver, the DATA-Waiver program required practitioners who wanted to prescribe buprenorphine to treat opioid use disorder (OUD) to register with the DEA and receive specialized training.

The DEA no longer will require additional registration to prescribe buprenorphine, only a standard DEA registration number, and has eliminated caps on the number of patients a prescriber may treat for OUD.

Along with the Substance Abuse and Mental Health Administration, the DEA is working on new training requirements that take effect June 21, and will provide further guidance.

Contact Senior Director of Policy Erin O’Malley at or 202.585.0127 with questions.


About the Author

Julie Kozminski is a policy manager at America's Essential Hospitals.

Previous Next
Test Caption
Test Description goes like this